Results of a new peer-reviewed study published on-line in the journal Free Radical Biology and Medicine clearly demonstrates that the synergistic impact of the active ingredients used in the formulation of the antioxidant Protandim dramatically increases the body's production of glutathione, a key antioxidant and anti-aging factor, as well as important antioxidant enzymes.
Protandim, a patented product developed by LifeVantage, was proven by an earlier study to actually slow the progressive rate of aging. This new study confirms that the product's gene induction approach to antioxidant therapy provides much broader and more powerful benefits to the body than those provided by vitamins such as E and C, according to the company.
Joe McCord, a co-author of the report, commented: "the results of this study may change how we view aging and the factors that impact healthy aging. Notably, glutathione, which is of particular interest to many disease researchers, was increased more than 300% with Protandim. Glutathione plays a key role in the immune system and when glutathione levels drop, a person's ability to fight disease also decreases. In addition to the findings on glutathione, the study also shows that Protandim delivers an antioxidant benefit to the body that exceeds those provided by vitamins E and C."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze